



INTELLIGENT  
**ULTRASOUND**<sup>®</sup>

*for smarter scanning*

# 2020 Preliminary Results

*Year ended 31 December 2020 (unaudited)*

# Important notice

The distribution of this Presentation in jurisdictions other than the UK may be restricted by law and persons into whose possession this document comes should inform themselves about and observe any relevant restrictions. In particular, this document may not be published or distributed, directly or indirectly, in or into the United States of America, Canada, Australia or Japan.

This Presentation made by Intelligent Ultrasound Group Plc does not constitute an offer of, or an invitation by or on behalf of the Company or anyone else to purchase or subscribe for, any securities of or investment in the Company in any circumstances. You are reminded that any purchase of securities or investment may be made solely on the basis of your own due diligence, investigations and assessment and solely on the basis of the relevant publicly available information and no reliance may be placed on the information contained in this document. This Presentation and the information contained within it are strictly confidential to the recipient, may not be distributed to any other person, and may not be further disclosed, copied or reproduced in any form, in whole or in part. Failure to comply with these restrictions may constitute a violation of applicable securities laws.

The information contained in this Presentation is for background purposes only, has not been independently verified by the Company nor any of the Company's directors, officers, shareholders, advisors or representatives. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. Save in the case of fraud, neither the Company nor any of its directors, officers, shareholders, advisors or representatives shall have any liability whatsoever for any loss arising from any use of this Presentation or its contents or otherwise arising in connection with this Presentation. By accepting this Presentation you agree, upon request, to return promptly all material received from the Company without retaining any copies.

This Presentation is not an invitation nor is it intended to be an inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000. This Presentation does not constitute or form part of and should not be construed as, an offer to sell or issue or the solicitation of an offer to buy or acquire securities of the Company in any jurisdiction or an inducement to enter into investment activity in any jurisdiction. In addition, this Presentation does not constitute a recommendation by the Company or any other person regarding any securities of, or an investment in, the Company. Neither this document nor any part thereof, nor the fact of its distribution, shall form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever.

This Presentation does not take into account the investment objectives, financial situation or particular needs of any particular investor, and it does not purport to be comprehensive or to contain all of the information that a prospective investor may desire or require in investigating the Company or an investment in the Company. Accordingly, each prospective investor should conduct its own due diligence in connection with any potential investment in the Company and seek the advice of its own professional advisors. Prospective investors must not treat the contents of this Presentation as advice relating to legal, taxation or investment matters and must make their own assessments concerning these and other consequences of any investment in the Company, including the merits of investment and the risks.

This Presentation is directed only at persons who (i) are "qualified investors" within the meaning of Article 21(1)(e) of Regulation 2017/1129/EU and any relevant implementing measures and (ii) are outside the United Kingdom, and/or (iii) have professional experience in matters relating to investments who fall within the definition of "investment professionals" contained in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"), or are persons falling within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc.) of the Order, or fall within another exemption to the Order (all such persons referred to in (i) to (iii) above together being referred to as "Relevant Persons"). Any person who is not a Relevant Person must not act or rely on this Presentation or any of its contents. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons.

This Presentation may include statements that are, or may be deemed to be, "forward-looking statements". Any forward-looking statements in this Presentation reflect the Company's current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. Forward-looking statements contained in this Presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Presentation.

# Summary – key milestones achieved

TWO AI PLATFORM PRODUCTS

MINIMISED COVID IMPACT ON SALES

STRENGTHENED BALANCE SHEET




LAUNCHED



CE APPROVED

April 2021



SIM REVENUE OF £5.2M

**£8.8M**  
CASH AT BANK  
*31 Dec 2020*

£4.8M PLACING

TRAINING

ULTRASOUND



INTELLIGENT  
ULTRASOUND®

“Our vision is to harness the power of the new generation of AI algorithms to make ultrasound simpler to use and easier to learn by providing guidance and support to medical professionals whilst they are scanning”

GUIDING

FOR EVERYONE

SUPPORTING

# Ultrasound for everyone

Medical Professionals

Consumer

CLASSROOM

CLINIC

AT HOME



Hi-fidelity simulators



AI-based software




Simulated Image

Current

Future

# CLINICAL AI DIVISION



# ScanNav Assist

- Launch of SonoLyst (incorporating ScanNav Assist AI technology) in Q4 2020
- Option on GE Healthcare's SWIFT ultrasound machine
  - World's first fully integrated AI tool that recognises the 20 views recommended by the International Society of Ultrasound in Obstetrics and Gynaecology (ISUOG) for **mid-trimester** fetal images
- SWIFT is one of three ultrasound machines sold in the Voluson Women's Health range
- Every SonoLyst option sold by GE Healthcare generates a royalty payment to Intelligent Ultrasound



## SonoLystIR

Performs automated detection of the key scanning views and automated selection of the relevant Voluson SonoBiometry measurement tools



## SonoLystX

A virtual onboard ultrasound expert that uses AI to compare the acquired image to standardised criteria, to ensure that it meets clinical standards

## SonoLyst

I have worked in the field of AI in ultrasound for over ten years, yet I am still amazed at the level of accuracy that has been achieved. You can really see how Intelligent Ultrasound's AI technology, incorporated in the SonoLyst software, will improve efficiency, make the learning of ultrasound easier and reduce omissions and errors. It's a big advance for ultrasound imaging in women's health.

Prof Aris Papageorgiou, Professor of Fetal Medicine, St George's Healthcare NHS Trust, London



# ScanNav Assist (cont)

- First indicative sales data expected to be available at interims
- 2021 focus on product roll-out and generating compelling key opinion leader study data to build market acceptance
- Enabling sales potential of AI in ultrasound to be realised from 2022 onwards



**SonoLyst**



# ScanNav Anatomy PNB

- Uses the latest AI from Intelligent Ultrasound
  - Automatically highlights the anatomical structures for 9 blocks on the live ultrasound image
- Compatible with general purpose ultrasound machines
  - with HDMI second monitor port
- Complete with block-specific 3D-animated training material
- Meets current Covid 19 cleaning requirements
  - Can be cleaned with medical grade disinfectants
- CE approved and in FDA regulatory process\*

In a validation study, regional anaesthesia experts judged the AI-driven colour highlighting to be helpful:

- for identifying anatomical structures in 1,330/1,334 cases (99.7%)
- for confirming the correct ultrasound view in 273/275 ultrasound scans (99.3%)

Bowness J, El-Boghdady K, Burckett-St Laurent D. **Artificial intelligence for image interpretation in ultrasound-guided regional anaesthesia.** Anaesthesia. 2020 Jul 29. doi: 10.1111/anae.15212. Epub ahead of print. PMID: 32726498.  
Turbitt LR, Mariano ER, El-Boghdady K. **Future directions in regional anaesthesia: not just for the cognoscenti.** Anaesthesia. 2020 Mar;75(3):293-297. doi: 10.1111/anae.14768. Epub 2019 Jul 3. PMID: 31268173.



**SCANNNAV**™  
**ANATOMY** Peripheral Nerve Block



# ScanNav Anatomy PNB (cont)


- 2021 focus on UK product roll-out on and generating the compelling key opinion leader study data to build acceptance
- 2022 anticipated roll-out extended to EU and USA (following FDA approval\*)
- Enabling sales potential of Anatomy PNB to be realised from 2022 onwards



**SCANNAV**™  
**ANATOMY** Peripheral Nerve Block

# Products in development

- ScanNav Detect aims to facilitate the automatic recognition of abnormalities within a general medical ultrasound scan
- Confirming that a clinician has correctly scanned the anatomical area of interest
- Then flagging any areas of potential abnormality, so the patient can be triaged to a specialist
- Products in development include:
  - Lung/Covid19 – good model progress in year
  - Liver – POC completed, and image partner agreed



SCANNAV™  
DETECT

# Future products

- ScanNav HealthCheck aims to develop the current ScanNav technology to enable consumers to perform ultrasound scans on themselves
- In the long term, as the price of the hardware comes down and the performance of our AI enabled software advances, we aim to provide enabling software for mass market AI-based ultrasound machines for home use, for the health-conscious consumer

SCANNAV®  
HEALTHCHECK



Simulated Image

# Ultrasound market volume estimates

## SCANNAV™

### ASSIST

Automated image analysis  
for protocol-based scanning




### ANATOMY

Automated anatomy highlighting  
for ultrasound guided needling



### DETECT

Automated pathology highlighting  
for ultrasound scanning



### HEALTHCHECK

Automated health check assessments  
Automated health check assessment  
for the worried well at home



## Directors estimate of total ultrasound machines in market

Women's Health ultrasound machines pa

30,000 (global)

Anesthesiology ultrasound machine pa

c. 6,000 (UK + USA)

Retrofit pool

c. 30,000 (UK + USA)

Emergency medicine, Critical Care and Radiology machine pa

c. 20,000 (UK + USA)

Retrofit pool

c. 100,000 (UK + USA)

300m worried well

# Clinical AI summary

## SCANNAV™

### ASSIST

Automated image analysis  
for protocol-based scanning




### ANATOMY

Automated anatomy highlighting  
for ultrasound guided needling



### DETECT

Automated pathology highlighting  
for ultrasound scanning



### HEALTHCHECK

Automated health check assessments

Automated health check assessment  
for the worried well at home



2020

2021

2022+

SonoLyst IR and SonoLyst X global launched on GE SWIFT

Development of additional products and variants

PNB in development

Launch PNB in UK and EU

Launch PNB outside UK and EU\*

\*subject to FDA approval

Prostate in development

Lung in development

Liver in development

Early-stage proof of concept

# SIMULATION DIVISION

- Three product platforms in 2020
- Expanding range throughout 2021
- Includes first AI enabled training simulator launched in March 2021

 BODYWORKS | Eve



PoCUS and Emergency

Covid19 case studies

 SCANTRAINER®



OBGYN

Upgrade in 2020

 HEARTWORKS®



Echo and Anaesthesia

New AR tablet

SCANNAV™  
ANATOMY Peripheral Nerve Block  
TRAINER




PNB

First AI sim March 2021

# Simulation division – minimising Covid19 impact

- Global sales declined by 13% to £5.2m (2019: £5.9m)
- Detailed breakdown in financial section
- Investment in new methods of selling to hospitals
- New web demonstration rooms in Cardiff and Atlanta
  - [Helping mitigate loss of face-to-face sales meetings](#)
- Early 2021 sales are encouraging




# GROUP: operational improvements

## Head office move to Hodge House in Cardiff in September 2020

- Increased R&D space to 3,000 sq ft
- Increased office space to 4,500 sq ft
- Dedicated web demonstration room for all simulation and clinical products
- Dedicated in-house clinical scanning area
- Enabling continued operations throughout pandemic

## Warehouse move to Caerphilly in July 2020

- Increased warehouse and tech support space to 5,000 sq ft
- Enabling all future simulation and clinical build and shipping to handled on one site



- Comprehensive meetings with shareholders throughout the year, including independent review
- By end of 2022 goal is to:
  - Reduce the size of the board to seven directors, with a majority of Independent non-executives
  - Increase board diversity and the relevant experience of the Directors in the ultrasound equipment market and in the evolving AI sector
- We expect 2021 will be a year of transition:
  - With new NEDs who are appointed overlapping with current Directors

*“Our goal is to build a sustainable and viable, long-term business that will enable ultrasound for everyone”*

 ESG Working Group established in April 2021 with the following remit:


- Hold regular ESG working group meetings in 2021 with CEO Stuart Gall as the accountable executive
- Develop an ESG policy that reflects our goal to build a sustainable and viable, long-term business that will enable ultrasound for everyone
- Develop and implement an environmental training/awareness programme for all employees
- Reduce the Group’s carbon emissions through initiatives such as
  - *minimising travel, paper use, printing and offsetting the Group’s 2021 carbon emissions*
- Develop an ESG dashboard that is reviewed annually and reported to stakeholders

# Financials


2020 unaudited preliminary results

# Financial Highlights


## Revenue




## Admin costs



## Operating loss



## Operating cashflows



Respectable performance in a difficult year


# Segment Performance Summary

|                | SIMULATION |      | CLINICAL AI |      | CENTRAL |      | GROUP |      |
|----------------|------------|------|-------------|------|---------|------|-------|------|
| £m             | 2020       | 2019 | 2020        | 2019 | 2020    | 2019 | 2020  | 2019 |
| Revenue        | 5.2        | 5.9  | -           | -    | -       | -    | 5.2   | 5.9  |
| Gross profit   | 3.2        | 3.5  | -           | -    | -       | -    | 3.2   | 3.5  |
| SG&A (exc R&D) | -4.4       | -4.5 | -0.5        | -0.6 | -0.9    | -0.8 | -5.8  | -6.0 |
| R&D*           | -0.9       | -1.2 | -1.7        | -1.5 | -       | -    | -2.6  | -2.7 |
| Operating loss | -1.3       | -1.6 | -2.3        | -2.1 | -0.9    | -0.8 | -4.5  | -4.6 |
| Loss after tax | -0.9       | -1.4 | -1.5        | -1.9 | -0.9    | -0.8 | -3.3  | -4.2 |

Top line impact of pandemic mitigated by lower SG&A costs

\* Includes capitalised R&D of £0.6m (2019: £0.5m) relating to the simulation division




# Improved operating cashflows



## Year end cash of £8.8m (2019: £7.3m)

- Increase of £1.5m from 2019
- Operating cash outflows improved by £1.0m on 2019
  - Tax credits: £0.4m
  - Working capital: £0.3m
- Capex includes £568k capitalised R&D spend (Simulation Division only)
- Positive working capital movement £0.3m
  - Receivables & payables: £0.7m
  - Increase in inventory: -£0.4m
- £4.8m share placing completed in May 2020

# Segment Revenue – Simulation Division




| FY | £5.2m | - 13% |
|----|-------|-------|
| H1 | £2.5m | - 20% |
| H2 | £2.7m | - 5%  |

- ⊕ Excellent UK performance - £1.4m v £0.7m ↑ 95%
- ⊕ Sales in H2 boosted by Covid-19 module on Bodyworks
- ⊖ NA revenue £2.3m v £2.6m ↓ 10% YOY. H2 sales ↑ by 60% on H1.
- ⊖ ROW region most impacted by COVID- £1.4m v £2.6m ↓ 46%

# Segment Performance – Simulation Division

| £m                  | 2020         | 2019         | YOY %        |
|---------------------|--------------|--------------|--------------|
| Revenue             | 5.2          | 5.9          | - 12.6%      |
| Gross profit        | 3.2          | 3.5          | -2.6%        |
| <i>Gross margin</i> | <i>61.3%</i> | <i>58.4%</i> | <i>+2.9%</i> |
| SG&A costs          | -4.7         | -5.2         | +2.2%        |
| Operating loss      | -1.3         | -1.6         | +15.4%       |



- ⊕ Lower revenues mitigated by savings in SG&A costs and GM gains - higher proportion of direct sales
- ⊕ Capex includes capitalised R&D of £0.5m – total R&D spend 2020: £0.9m (2019: £1.2m)
  - ⊕ Covid-19 module/HeartWorks AR Tablet/ScanTrainer module

Improved operating losses despite lower revenues

# Segment Performance – Clinical AI Division


| £m             | 2020 | 2019 |  |
|----------------|------|------|--|
| Revenue        | *    | -    | First AI revenues in Q4 2020 - *£17k         |
| R&D costs      | -1.7 | -1.5 | Headcount increase of 6 to 21                |
| Operating loss | -2.3 | -2.1 |  |
| Tax credit     | 0.7  | 0.2  | 2019 and 2020 tax credits recognised in 2020 |
| Loss after tax | -1.5 | -1.9 |  |

## Main R&D Activity

- ScanNav Assist
- ScanNav Anatomy PNB
- New product development (lung)
- Includes external consultancy costs £0.5m

# Strong financial position

Net assets £m



|                             |   | 2020<br>£m  | 2019<br>£m  |
|-----------------------------|---|-------------|-------------|
| Non-current assets          | 1 | 3.3         | 2.9         |
| Current assets              |   |             |             |
| - Inventory                 | 2 | 1.0         | 0.7         |
| - Trade & other receivables | 3 | 2.0         | 2.7         |
| - R&D tax credit            |   | 0.4         | 0.1         |
| - Cash                      |   | 8.8         | 7.3         |
| Current liabilities         |   | (2.2)       | (2.1)       |
| Non-current liabilities     |   | (0.9)       | (0.5)       |
| <b>Net assets</b>           |   | <b>12.7</b> | <b>11.1</b> |

1

Includes IFRS 16 assets for new office & warehouse of £0.7m

2

Move to larger premises ensured we could increase stock levels in anticipation of potential supply chain disruption due to Covid-19 and Brexit and future direct AI sales

3

Timing combined with increased focus on debtor collection

# Summary

- Key clinical AI milestones achieved:
  - First AI software with GE launched and selling in global obstetric market
  - Second AI software for PNB received CE approval
- Key simulation targets achieved:
  - Mitigated impact of pandemic on revenue in adverse operating market
  - Launched Covid-19 module for BodyWorks
- Key group targets achieved
  - Reduced EBITDA losses, despite reduced turnover
  - Strengthened balance sheet
- Encouraging start to 2021
- Group continues to expect to reach profitability inflexion point with existing cash



INTELLIGENT  
**ULTRASOUND**<sup>®</sup>

*for smarter scanning*



[www.intelligentultrasound.com](http://www.intelligentultrasound.com)